Lower Merion Township, Pennsylvania, United States · Hybrid
Description The Company: This publicly held clinical-stage biotechnology company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology p…
Skills: Computer System Validation, Computer Software Assurance, Data Integrity, GxP Compliance, Risk Assessment
Lower Merion Township, Pennsylvania, United States • Hybrid
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
Provide quality oversight for GxP computer systems and manage the company's data integrity program to ensure regulatory compliance. This includes reviewing validation documentation, managing risk assessments, and serving as a subject matter expert during audits and inspections.
Requires a Bachelor's degree in a scientific or technical discipline and 8+ years of quality experience in biotech/pharma, including 3 years in GxP computer systems validation. Must have a strong understanding of 21 CFR Part 11, EU Annex 11, and GAMP 5 concepts.
Description
This publicly held clinical-stage biotechnology company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Their lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. Friedreich’s ataxia is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality.
The company has 80 employees and has assembled an experienced management team, each of whom has over 20 years of pharmaceutical industry experience. The management team, employees, and consultants have significant expertise in discovery, nonclinical and clinical development, regulatory affairs, commercialization, and the development of manufacturing processes utilizing good manufacturing practices (GMPs).
The company’s strategy is to become a leader in the treatment of rare diseases by leveraging their technology platform and applying their team’s know-how and expertise to the development of CTI-1601 and other future pipeline programs. They are best characterized by entrepreneurial and scientific leadership and a participatory workforce committed to success.
The Associate Director/Director, Quality, Validation and Data Integrity will be responsible to provide quality support and oversight for Larimar’s GxP Computer Systems and to manage Larimar’s Data Integrity program, ensuring compliance with relevant regulatory requirements and industry standards/best practices. This position reports to the Senior Director, Quality.
This role will require being in the office located in Bala Cynwyd, PA. At the current time, the number of days in the office is flexible and may change over time.
The responsibilities for the Associate Director/Director, Quality, Validation and Data Integrity may include, but are not limited to the following activities:
Requirements
Title and compensation will be dependent on years of experience and qualifications. This role requires a Bachelor’s degree in a scientific or technical discipline and 8+ years of experience in a Quality role in the biotechnology/pharmaceutical industry with at least 3 years’ direct experience with GxP computer systems validation. Experience with GxP validation methodology is required. Strong understanding of 21 CFR Part 11, EU Annex 11 regulations, GAMP 5 concepts, applications and best practices is required. Must possess strong attention to detail while having the ability to work independently and collaboratively in a fast-paced environment. Demonstrated ability to initiate process improvements, set priorities and meet aggressive timelines is required.
Larimar Therapeutics offers all employees incentive stock options, a comprehensive benefits plan including 401K, and a flexible PTO policy.
Equal Opportunity Employment
We are committed to equal-employment principles, and we recognize the value of committed employees who feel they are being treated in an equitable and professional manner. We strive to find ways to attract, develop and retain the talent needed to meet business objectives, and to recruit and employ highly qualified individuals representing the diverse communities in which we live.
Employment policies and decisions on employment and promotion are based on merit, qualifications, performance, and business needs. The decisions and criteria governing the employment relationship with all employees are made in a non-discriminatory manner—without regard to age, race, color, national origin, gender (including pregnancy, childbirth or medical condition related to pregnancy or childbirth), gender identity or expression, religion, physical or mental disability, medical condition, legally protected genetic information, marital status, veteran status, military status, sexual orientation, or any other factor determined to be an unlawful basis for such decisions by federal, state, or local statutes.
Clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Offices: Three Bala Plaza East, Suite 506, Bala Cynwyd, PA 19004, US · 4500 East 75th Street, Indianapolis, Indiana 46250, US
Clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Offices: Three Bala Plaza East, Suite 506, Bala Cynwyd, PA 19004, US · 4500 East 75th Street, Indianapolis, Indiana 46250, US
